An analysis of 54 new cancer drugs found that over the last decade the FDA allowed 74% of them on the market without proof that they extended life. Seldom was there proof of improved quality of life, either.
JSOnline.com HL - Metro Top Stories, Milwaukee Journal Sentinel: Local
Sat, 10/25/2014 - 10:01pm
An analysis of 54 new cancer drugs found that over the last decade the FDA allowed 74% of them on the market without proof that they extended life. Seldom was there proof of improved quality of life, either.